Movetis | Gastroenterology in motion

Movetis focuses on the discovery, development and commercialisation of novel innovative drugs for the treatment of gastrointestinal diseases with high unmet need.

Movetis is developing its own commercial infrastructure in selected EU markets (Germany, UK, the Netherlands, Belgium, Luxemburg and France) and will work with partners in other countries.

Prucalopride study data in elderly CC patients published:

prucalopride approved in the European Economic Area...

first step in label expansion strategy for prucalopride

Movetis at ACPGBI annual meeting in Bournemouth (UK)

Innovation in Gastroenterology

Other Movetis Websites

Availability of Resolor® (prucalopride)

Annual Report